http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021165292-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f671e91cb8c71df9764cfeccf0a2e1d9 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2021-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b313fb992772a20225275acd5dd7bb9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fabee5cda3f83c6ebd57384e33b4263a |
| publicationDate | 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2021165292-A |
| titleOfInvention | Hematopoietic tumor therapeutic agent and screening method |
| abstract | PROBLEM TO BE SOLVED: To provide a novel therapeutic agent for hematopoietic tumors which is effective for treating hematopoietic tumors (particularly acute leukemia such as AML and ALL). SOLUTION: As the present invention, for example, a hematopoietic tumor therapeutic agent characterized by containing an SMS2 inhibitor, an anti-SMS2 antibody, or a human bone marrow cell or an immune cell lacking the SMS2 gene as an active ingredient can be mentioned. Can be done. According to the present invention, it is useful for enhancing antitumor immune activity and treating hematopoietic tumors (particularly acute leukemia). [Selection diagram] Fig. 1 |
| priorityDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.